APO Research
Talk to an analyst

APO RESEARCH · REPORT

Biomarker Clinical Phase Outsourcing Services

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Biomarker Clinical Phase Outsourcing Services Market Outlook and Growth Opportunities 2026

4 March 2026191 pages

Choose your research edition.

Industry ResearchBiomarker Clinical Phase Outsourcing Services Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Biomarker Clinical Phase Outsourcing Services Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Biomarker Clinical Phase Outsourcing Services Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biomarker Clinical Phase Outsourcing Services Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Biomarker Clinical Phase Outsourcing Services Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Biomarker Clinical Phase Outsourcing Services market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Biomarker Clinical Phase Outsourcing Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Biomarker Clinical Phase Outsourcing Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Biomarker Clinical Phase Outsourcing Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Biomarker Clinical Phase Outsourcing Services market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Biomarker Clinical Phase Outsourcing Services market include ICON plc, Fujirebio lnc, Charles River Laboratories International,Inc., Laboratory Corporation of America Holdings, Parexel lnternational Corporation, Proteome Sciences plc, Eurofins Scientific, Wuxi AppTec Co., Ltd. and NorthEast BioAnalytical Laboratories LLC., among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Biomarker Clinical Phase Outsourcing Services market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Biomarker Clinical Phase Outsourcing Services and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Biomarker Clinical Phase Outsourcing Services revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Biomarker Clinical Phase Outsourcing Services market.

Biomarker Clinical Phase Outsourcing Services Segment by Company

ICON plc

Fujirebio lnc

Charles River Laboratories International,Inc.

Laboratory Corporation of America Holdings

Parexel lnternational Corporation

Proteome Sciences plc

Eurofins Scientific

Wuxi AppTec Co., Ltd.

NorthEast BioAnalytical Laboratories LLC.

Celerion, Inc.

GenScript ProBio Co.,Ltd.

Biomarker Clinical Phase Outsourcing Services Segment by Type

Predictive Biomarker

Prognostic Biomarker

Safety Biomarker

Surrogate Endpoints

Biomarker Clinical Phase Outsourcing Services Segment by Application

Pharmaceutical Companies

Biotechnology Companies

Others

Biomarker Clinical Phase Outsourcing Services Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Biomarker Clinical Phase Outsourcing Services status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Biomarker Clinical Phase Outsourcing Services key companies, revenue, market share, and recent developments.

3. To split the Biomarker Clinical Phase Outsourcing Services breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Biomarker Clinical Phase Outsourcing Services market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Biomarker Clinical Phase Outsourcing Services significant trends, drivers, influence factors in global and regions.

6. To analyze Biomarker Clinical Phase Outsourcing Services competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biomarker Clinical Phase Outsourcing Services market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biomarker Clinical Phase Outsourcing Services and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biomarker Clinical Phase Outsourcing Services.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Biomarker Clinical Phase Outsourcing Services industry.

Chapter 3: Detailed analysis of Biomarker Clinical Phase Outsourcing Services company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Biomarker Clinical Phase Outsourcing Services in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Biomarker Clinical Phase Outsourcing Services in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Biomarker Clinical Phase Outsourcing Services Industry Trends Table 2. Biomarker Clinical Phase Outsourcing Services Industry Drivers Table 3. Biomarker Clinical Phase Outsourcing Services Industry Opportunities and Challenges Table 4. Biomarker Clinical Phase Outsourcing Services Industry Restraints Table 5. Global Biomarker Clinical Phase Outsourcing Services Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Biomarker Clinical Phase Outsourcing Services Revenue Share by Company (2021-2026) Table 7. Global Biomarker Clinical Phase Outsourcing Services Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Biomarker Clinical Phase Outsourcing Services Key Company Manufacturing Base & Headquarters Table 9. Global Biomarker Clinical Phase Outsourcing Services Company, Product Type & Application Table 10. Global Biomarker Clinical Phase Outsourcing Services Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Biomarker Clinical Phase Outsourcing Services by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Predictive Biomarker Table 15. Significant Companies of Prognostic Biomarker Table 16. Significant Companies of Safety Biomarker Table 17. Significant Companies of Surrogate Endpoints Table 18. Global Biomarker Clinical Phase Outsourcing Services Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Biomarker Clinical Phase Outsourcing Services Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Biomarker Clinical Phase Outsourcing Services Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type (2021-2026) Table 22. Global Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Pharmaceutical Companies Table 24. Significant Companies of Biotechnology Companies Table 25. Significant Companies of Others Table 26. Global Biomarker Clinical Phase Outsourcing Services Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Biomarker Clinical Phase Outsourcing Services Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Biomarker Clinical Phase Outsourcing Services Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application (2021-2026) Table 30. Global Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application (2027-2032) Table 31. Global Biomarker Clinical Phase Outsourcing Services Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Biomarker Clinical Phase Outsourcing Services Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Biomarker Clinical Phase Outsourcing Services Sales Value Share by Region (2021-2026) Table 34. Global Biomarker Clinical Phase Outsourcing Services Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Biomarker Clinical Phase Outsourcing Services Sales Value Share by Region (2027-2032) Table 36. Global Biomarker Clinical Phase Outsourcing Services Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Biomarker Clinical Phase Outsourcing Services Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Biomarker Clinical Phase Outsourcing Services Sales Value Market Share by Country (2021-2026) Table 39. Global Biomarker Clinical Phase Outsourcing Services Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Biomarker Clinical Phase Outsourcing Services Sales Value Market Share by Country (2027-2032) Table 41. ICON plc Company Information Table 42. ICON plc Business Overview Table 43. ICON plc Biomarker Clinical Phase Outsourcing Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. ICON plc Biomarker Clinical Phase Outsourcing Services Product Portfolio Table 45. ICON plc Recent Development Table 46. Fujirebio lnc Company Information Table 47. Fujirebio lnc Business Overview Table 48. Fujirebio lnc Biomarker Clinical Phase Outsourcing Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Fujirebio lnc Biomarker Clinical Phase Outsourcing Services Product Portfolio Table 50. Fujirebio lnc Recent Development Table 51. Charles River Laboratories International,Inc. Company Information Table 52. Charles River Laboratories International,Inc. Business Overview Table 53. Charles River Laboratories International,Inc. Biomarker Clinical Phase Outsourcing Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Charles River Laboratories International,Inc. Biomarker Clinical Phase Outsourcing Services Product Portfolio Table 55. Charles River Laboratories International,Inc. Recent Development Table 56. Laboratory Corporation of America Holdings Company Information Table 57. Laboratory Corporation of America Holdings Business Overview Table 58. Laboratory Corporation of America Holdings Biomarker Clinical Phase Outsourcing Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Laboratory Corporation of America Holdings Biomarker Clinical Phase Outsourcing Services Product Portfolio Table 60. Laboratory Corporation of America Holdings Recent Development Table 61. Parexel lnternational Corporation Company Information Table 62. Parexel lnternational Corporation Business Overview Table 63. Parexel lnternational Corporation Biomarker Clinical Phase Outsourcing Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Parexel lnternational Corporation Biomarker Clinical Phase Outsourcing Services Product Portfolio Table 65. Parexel lnternational Corporation Recent Development Table 66. Proteome Sciences plc Company Information Table 67. Proteome Sciences plc Business Overview Table 68. Proteome Sciences plc Biomarker Clinical Phase Outsourcing Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Proteome Sciences plc Biomarker Clinical Phase Outsourcing Services Product Portfolio Table 70. Proteome Sciences plc Recent Development Table 71. Eurofins Scientific Company Information Table 72. Eurofins Scientific Business Overview Table 73. Eurofins Scientific Biomarker Clinical Phase Outsourcing Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Eurofins Scientific Biomarker Clinical Phase Outsourcing Services Product Portfolio Table 75. Eurofins Scientific Recent Development Table 76. Wuxi AppTec Co., Ltd. Company Information Table 77. Wuxi AppTec Co., Ltd. Business Overview Table 78. Wuxi AppTec Co., Ltd. Biomarker Clinical Phase Outsourcing Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Wuxi AppTec Co., Ltd. Biomarker Clinical Phase Outsourcing Services Product Portfolio Table 80. Wuxi AppTec Co., Ltd. Recent Development Table 81. NorthEast BioAnalytical Laboratories LLC. Company Information Table 82. NorthEast BioAnalytical Laboratories LLC. Business Overview Table 83. NorthEast BioAnalytical Laboratories LLC. Biomarker Clinical Phase Outsourcing Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. NorthEast BioAnalytical Laboratories LLC. Biomarker Clinical Phase Outsourcing Services Product Portfolio Table 85. NorthEast BioAnalytical Laboratories LLC. Recent Development Table 86. Celerion, Inc. Company Information Table 87. Celerion, Inc. Business Overview Table 88. Celerion, Inc. Biomarker Clinical Phase Outsourcing Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Celerion, Inc. Biomarker Clinical Phase Outsourcing Services Product Portfolio Table 90. Celerion, Inc. Recent Development Table 91. GenScript ProBio Co.,Ltd. Company Information Table 92. GenScript ProBio Co.,Ltd. Business Overview Table 93. GenScript ProBio Co.,Ltd. Biomarker Clinical Phase Outsourcing Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. GenScript ProBio Co.,Ltd. Biomarker Clinical Phase Outsourcing Services Product Portfolio Table 95. GenScript ProBio Co.,Ltd. Recent Development Table 96. Research Programs/Design for This Report Table 97. Authors List of This Report Table 98. Secondary Sources Table 99. Primary Sources List of Figures Figure 1. Biomarker Clinical Phase Outsourcing Services Product Image Figure 2. Global Biomarker Clinical Phase Outsourcing Services Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biomarker Clinical Phase Outsourcing Services Market Size (2021-2032) & (US$ Million) Figure 4. Global Biomarker Clinical Phase Outsourcing Services Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Predictive Biomarker Image Figure 8. Prognostic Biomarker Image Figure 9. Safety Biomarker Image Figure 10. Surrogate Endpoints Image Figure 11. Global Biomarker Clinical Phase Outsourcing Services Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Biomarker Clinical Phase Outsourcing Services Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type (2021-2032) Figure 14. Pharmaceutical Companies Image Figure 15. Biotechnology Companies Image Figure 16. Others Image Figure 17. Global Biomarker Clinical Phase Outsourcing Services Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Biomarker Clinical Phase Outsourcing Services Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application (2021-2032) Figure 20. Global Biomarker Clinical Phase Outsourcing Services Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Biomarker Clinical Phase Outsourcing Services Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Biomarker Clinical Phase Outsourcing Services Sales Value (2021-2032) & (US$ Million) Figure 23. North America Biomarker Clinical Phase Outsourcing Services Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Biomarker Clinical Phase Outsourcing Services Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Biomarker Clinical Phase Outsourcing Services Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Biomarker Clinical Phase Outsourcing Services Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Biomarker Clinical Phase Outsourcing Services Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Biomarker Clinical Phase Outsourcing Services Sales Value (2021-2032) & (US$ Million) Figure 29. South America Biomarker Clinical Phase Outsourcing Services Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Biomarker Clinical Phase Outsourcing Services Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Biomarker Clinical Phase Outsourcing Services Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Predictive Biomarker
  • Prognostic Biomarker
  • Safety Biomarker
  • Surrogate Endpoints
Applications
  • Pharmaceutical Companies
  • Biotechnology Companies
  • Others
Companies covered
  • ICON plc
  • Fujirebio lnc
  • Charles River Laboratories International,Inc.
  • Laboratory Corporation of America Holdings
  • Parexel lnternational Corporation
  • Proteome Sciences plc
  • Eurofins Scientific
  • Wuxi AppTec Co., Ltd.
  • NorthEast BioAnalytical Laboratories LLC.
  • Celerion, Inc.
  • GenScript ProBio Co.,Ltd.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Biomarker Clinical Phase Outsourcing Services Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Biomarker Clinical Phase Outsourcing Services Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Biomarker Clinical Phase Outsourcing Services Market Dynamics
  1. 2.1 Biomarker Clinical Phase Outsourcing Services Industry Trends
  2. 2.2 Biomarker Clinical Phase Outsourcing Services Industry Drivers
  3. 2.3 Biomarker Clinical Phase Outsourcing Services Industry Opportunities and Challenges
  4. 2.4 Biomarker Clinical Phase Outsourcing Services Industry Restraints
3 Biomarker Clinical Phase Outsourcing Services Market by Company
  1. 3.1 Global Biomarker Clinical Phase Outsourcing Services Company Revenue Ranking in 2025
  2. 3.2 Global Biomarker Clinical Phase Outsourcing Services Revenue by Company (2021-2026)
  3. 3.3 Global Biomarker Clinical Phase Outsourcing Services Company Ranking (2024-2026)
  4. 3.4 Global Biomarker Clinical Phase Outsourcing Services Company Manufacturing Base and Headquarters
  5. 3.5 Global Biomarker Clinical Phase Outsourcing Services Company Product Type and Application
  6. 3.6 Global Biomarker Clinical Phase Outsourcing Services Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Biomarker Clinical Phase Outsourcing Services Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Biomarker Clinical Phase Outsourcing Services Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Biomarker Clinical Phase Outsourcing Services Market by Type
  1. 4.1 Biomarker Clinical Phase Outsourcing Services Type Introduction
  2. 4.1.1 Predictive Biomarker
  3. 4.1.2 Prognostic Biomarker
  4. 4.1.3 Safety Biomarker
  5. 4.1.4 Surrogate Endpoints
  6. 4.2 Global Biomarker Clinical Phase Outsourcing Services Sales Value by Type
  7. 4.2.1 Global Biomarker Clinical Phase Outsourcing Services Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Biomarker Clinical Phase Outsourcing Services Sales Value by Type (2021-2032)
  9. 4.2.3 Global Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type (2021-2032)
5 Biomarker Clinical Phase Outsourcing Services Market by Application
  1. 5.1 Biomarker Clinical Phase Outsourcing Services Application Introduction
  2. 5.1.1 Pharmaceutical Companies
  3. 5.1.2 Biotechnology Companies
  4. 5.1.3 Others
  5. 5.2 Global Biomarker Clinical Phase Outsourcing Services Sales Value by Application
  6. 5.2.1 Global Biomarker Clinical Phase Outsourcing Services Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Biomarker Clinical Phase Outsourcing Services Sales Value by Application (2021-2032)
  8. 5.2.3 Global Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application (2021-2032)
6 Biomarker Clinical Phase Outsourcing Services Regional Value Analysis
  1. 6.1 Global Biomarker Clinical Phase Outsourcing Services Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Biomarker Clinical Phase Outsourcing Services Sales Value by Region (2021-2032)
  3. 6.2.1 Global Biomarker Clinical Phase Outsourcing Services Sales Value by Region: 2021-2026
  4. 6.2.2 Global Biomarker Clinical Phase Outsourcing Services Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Biomarker Clinical Phase Outsourcing Services Sales Value (2021-2032)
  7. 6.3.2 North America Biomarker Clinical Phase Outsourcing Services Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Biomarker Clinical Phase Outsourcing Services Sales Value (2021-2032)
  10. 6.4.2 Europe Biomarker Clinical Phase Outsourcing Services Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Biomarker Clinical Phase Outsourcing Services Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Biomarker Clinical Phase Outsourcing Services Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Biomarker Clinical Phase Outsourcing Services Sales Value (2021-2032)
  16. 6.6.2 South America Biomarker Clinical Phase Outsourcing Services Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Biomarker Clinical Phase Outsourcing Services Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Biomarker Clinical Phase Outsourcing Services Sales Value Share by Country, 2025 VS 2032
7 Biomarker Clinical Phase Outsourcing Services Country-level Value Analysis
  1. 7.1 Global Biomarker Clinical Phase Outsourcing Services Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Biomarker Clinical Phase Outsourcing Services Sales Value by Country (2021-2032)
  3. 7.2.1 Global Biomarker Clinical Phase Outsourcing Services Sales Value by Country (2021-2026)
  4. 7.2.2 Global Biomarker Clinical Phase Outsourcing Services Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Biomarker Clinical Phase Outsourcing Services Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Biomarker Clinical Phase Outsourcing Services Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Biomarker Clinical Phase Outsourcing Services Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 ICON plc
  2. 8.1.1 ICON plc Company Information
  3. 8.1.2 ICON plc Business Overview
  4. 8.1.3 ICON plc Biomarker Clinical Phase Outsourcing Services Revenue and Gross Margin (2021-2026)
  5. 8.1.4 ICON plc Biomarker Clinical Phase Outsourcing Services Product Portfolio
  6. 8.1.5 ICON plc Recent Developments
  7. 8.2 Fujirebio lnc
  8. 8.2.1 Fujirebio lnc Company Information
  9. 8.2.2 Fujirebio lnc Business Overview
  10. 8.2.3 Fujirebio lnc Biomarker Clinical Phase Outsourcing Services Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Fujirebio lnc Biomarker Clinical Phase Outsourcing Services Product Portfolio
  12. 8.2.5 Fujirebio lnc Recent Developments
  13. 8.3 Charles River Laboratories International,Inc.
  14. 8.3.1 Charles River Laboratories International,Inc. Company Information
  15. 8.3.2 Charles River Laboratories International,Inc. Business Overview
  16. 8.3.3 Charles River Laboratories International,Inc. Biomarker Clinical Phase Outsourcing Services Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Charles River Laboratories International,Inc. Biomarker Clinical Phase Outsourcing Services Product Portfolio
  18. 8.3.5 Charles River Laboratories International,Inc. Recent Developments
  19. 8.4 Laboratory Corporation of America Holdings
  20. 8.4.1 Laboratory Corporation of America Holdings Company Information
  21. 8.4.2 Laboratory Corporation of America Holdings Business Overview
  22. 8.4.3 Laboratory Corporation of America Holdings Biomarker Clinical Phase Outsourcing Services Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Laboratory Corporation of America Holdings Biomarker Clinical Phase Outsourcing Services Product Portfolio
  24. 8.4.5 Laboratory Corporation of America Holdings Recent Developments
  25. 8.5 Parexel lnternational Corporation
  26. 8.5.1 Parexel lnternational Corporation Company Information
  27. 8.5.2 Parexel lnternational Corporation Business Overview
  28. 8.5.3 Parexel lnternational Corporation Biomarker Clinical Phase Outsourcing Services Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Parexel lnternational Corporation Biomarker Clinical Phase Outsourcing Services Product Portfolio
  30. 8.5.5 Parexel lnternational Corporation Recent Developments
  31. 8.6 Proteome Sciences plc
  32. 8.6.1 Proteome Sciences plc Company Information
  33. 8.6.2 Proteome Sciences plc Business Overview
  34. 8.6.3 Proteome Sciences plc Biomarker Clinical Phase Outsourcing Services Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Proteome Sciences plc Biomarker Clinical Phase Outsourcing Services Product Portfolio
  36. 8.6.5 Proteome Sciences plc Recent Developments
  37. 8.7 Eurofins Scientific
  38. 8.7.1 Eurofins Scientific Company Information
  39. 8.7.2 Eurofins Scientific Business Overview
  40. 8.7.3 Eurofins Scientific Biomarker Clinical Phase Outsourcing Services Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Eurofins Scientific Biomarker Clinical Phase Outsourcing Services Product Portfolio
  42. 8.7.5 Eurofins Scientific Recent Developments
  43. 8.8 Wuxi AppTec Co., Ltd.
  44. 8.8.1 Wuxi AppTec Co., Ltd. Company Information
  45. 8.8.2 Wuxi AppTec Co., Ltd. Business Overview
  46. 8.8.3 Wuxi AppTec Co., Ltd. Biomarker Clinical Phase Outsourcing Services Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Wuxi AppTec Co., Ltd. Biomarker Clinical Phase Outsourcing Services Product Portfolio
  48. 8.8.5 Wuxi AppTec Co., Ltd. Recent Developments
  49. 8.9 NorthEast BioAnalytical Laboratories LLC.
  50. 8.9.1 NorthEast BioAnalytical Laboratories LLC. Company Information
  51. 8.9.2 NorthEast BioAnalytical Laboratories LLC. Business Overview
  52. 8.9.3 NorthEast BioAnalytical Laboratories LLC. Biomarker Clinical Phase Outsourcing Services Revenue and Gross Margin (2021-2026)
  53. 8.9.4 NorthEast BioAnalytical Laboratories LLC. Biomarker Clinical Phase Outsourcing Services Product Portfolio
  54. 8.9.5 NorthEast BioAnalytical Laboratories LLC. Recent Developments
  55. 8.10 Celerion, Inc.
  56. 8.10.1 Celerion, Inc. Company Information
  57. 8.10.2 Celerion, Inc. Business Overview
  58. 8.10.3 Celerion, Inc. Biomarker Clinical Phase Outsourcing Services Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Celerion, Inc. Biomarker Clinical Phase Outsourcing Services Product Portfolio
  60. 8.10.5 Celerion, Inc. Recent Developments
  61. 8.11 GenScript ProBio Co.,Ltd.
  62. 8.11.1 GenScript ProBio Co.,Ltd. Company Information
  63. 8.11.2 GenScript ProBio Co.,Ltd. Business Overview
  64. 8.11.3 GenScript ProBio Co.,Ltd. Biomarker Clinical Phase Outsourcing Services Revenue and Gross Margin (2021-2026)
  65. 8.11.4 GenScript ProBio Co.,Ltd. Biomarker Clinical Phase Outsourcing Services Product Portfolio
  66. 8.11.5 GenScript ProBio Co.,Ltd. Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst